[Advances in the diagnosis and treatment of hepatitis C virus infection in patients with and without HIV infection].
The chronic infection by the hepatits C virus represents a serious sanitary problem affecting 1-3% of the world-wide population. It is transmitted by sexual route, vertical route and mainly after blood exposure by percutanea route. While HIV shares similar routes of transmission, the co-infection HCV-HIV is very frequent and the chronic hepatopathy and complications associated with its clinical course are an important cause of morbi-mortality in this population. The gold standard of the treatment for the HCV, has been the interferon and later the combination therapy of interferon plus ribavirine. Currently, the combination of ribavirine and a new pegilated formulation of the interferon has become the standard in the treatment reaching rates of sustained viral response around 40-80%.
Laguno
Montse
M
Servicio de Enfermedades Infecciosas, Hospital Clínic-Universitari de Barcelona-IDIBAPS, Universitat de Barcelona, Spain.
Sánchez-Tapias
José María
JM
Murillas
Javier
J
Forns
Xavier
X
Blanco
José L
JL
Martínez
Esteban
E
Larrousse
María
M
León
Agathe
A
Loncá
Montse
M
Milinkovic
Ana
A
Miró
José M
JM
García
Felipe
F
Gatell
José María
JM
Mallolas
Josep
J
D000014:Abnormalities, Drug-Induced / Q000209:etiology; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use; D001706:Biopsy; D015897:Comorbidity; D018450:Disease Progression; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000453:epidemiology; D006402:Hematologic Diseases / Q000139:chemically induced; D006526:Hepatitis C / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy* / Q000453:epidemiology / Q000635:transmission; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use; D008099:Liver / Q000473:pathology / Q000821:virology; D008297:Male; D012254:Ribavirin / Q000009:adverse effects / Q000627:therapeutic use
D000998:Antiviral Agents; D016898:Interferon-alpha; D012254:Ribavirin